Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.

Monday, Sep 22, 2025 6:01 am ET1min read

Ascendiant Capital maintains Buy on Outlook Therapeutics, lowers PT to $8.

Comments



Add a public comment...
No comments

No comments yet